| I |
|
Identification and characterisation of MIP-1b and VE-Cadherin as important markers of acute rejection after human heart transplantation
|
| Roussoulieres A. L. S., Raisky O., Chalabreysse L., Dureau G., Cerrutti C., Boissonnat P., Sebbag L., Gare J. - P., Obadia J. F., Ninet J., Bastien O., Thivolet-Bejui F., Mcgregor J. L. |
| |
|
Identification and expression of the first type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene
|
| Hilbert L., D'Oiron R., Fressinaud E., Meyer D., Mazurier C. |
| |
|
Identification of a binding site for glycoprotein Iba in the Apple 3 domain of factor XI
|
| Baglia F. A., Lopez J. A., Walsh P. N. |
| |
|
Identification of a dysfibrinogenemia characterized by marked resistance to fibrinolysis in an asymptomatic woman
|
| Colucci M., Piro D., Pentimone A., Ranieri P., Micelli M., Semeraro N. |
| |
|
Identification of a Factor IX cleaving protease and efficient reduction in a high purity Factor IX manufacturing process
|
| Kundu S., Bigler D., Lind H., Schulte S. |
| |
|
Identification of a family with discrepant von Willebrand factor collagen binding assays (VWF:CB)
|
| Riddell A., Mellars G., Andrews V., Hayes J. P. L. A., Brown S.A. |
| |
|
Identification of a novel inhibitory monoclonal antibody against the integrin a2b1
|
| Schoolmeester A., Vauterin S., Vanhoorelbeke K., Deckmyn H. |
| |
|
Identification of a quantal unit mediating platelet tethering and microparticle formation through glycoprotein Ibalpha–VWF interaction
|
| Reininger A. J., Ruggeri Z. M. |
| |
|
Identification of a tissue factor ortholog in zebrafish, a potential new animal model of hemostasis and cancer
|
| Ingersoll S. B., Meyer T. V., Plank D. M., Amirkhosravi A., Francis J. L. |
| |
|
Identification of amino acids in antiplasmin involved in the noncovalent ‘lysine-binding site’ dependent interaction with plasmin
|
| Wang H., Pap S., Yu A., Wiman B. |
| |
|
Identification of an integrin-associated chloride channel in human platelets
|
| Larkin D., Reilly D., Edwards R. J., Cahill D. J., Moran N. |
| |
|
Identification of factor IX mutations in 17 Iranian families with hemophilia B
|
| Enayat M. S., Theophilus B. D. M., Farjadian S., Karimi M., Hill F. G. H. |
| |
|
Identification of individuals at high risk of developing Ischaemic Heart Diseases
|
| De Lorenzo F., Izon D., Kakkar V. V. |
| |
|
Identification of intron 1 and 22 inversion mutation in the factor VIII gene of 94 Iranian families with hemophilia A
|
| Rastegar Lari G., Arjang Z., Pejhan N., Baghaipoor M. R., Lavergne J. M., Enayat M. S., Ala F. |
| |
|
Identification of seven new candidate mutations of ADAMTS13 gene in four French families related to congenital thrombotic thrombocytopenic purpura
|
| Veyradier A., Lavergne J. M., Obert B., Ribba A. S., Fressinaud E., Loirat C., Meyer D., Girma J. P. |
| |
|
Identification of six novel mutations in families with type 3 von Willebrand disease
|
| Guilliatt A. M., Enayat M. S., Surdhar G. K., Bolton-Maggs P., Wilde J. T., Hill F. G. H. |
| |
|
Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease
|
| Banno F., Kaminaka K., Soejima K., Kokame K., Miyata T. |
| |
|
Identification of the bitiscetin-binding site on the von Willebrand factor A3-domain. Comparison to the collagen-binding site
|
| Obert B., Romijn R. A. P., Houllier A., Huizinga E., Girma J. P. |
| |
|
Identification of the multimerin binding region within the C2 domain of human factor V using constructs generated by alanine scanning and site-directed mutagenesis
|
| Woram R. A., Kane W. H., Quinn-Allen M. A., Nicolaes G. A. F., Dahlback B., Hayward C. P. M. |
| |
|
Identification of transcription factor binding sites for HNF1-alpha, FOXA2, HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer
|
| Ceelie H., Spaargaren-Van Riel C. C., De Jong M., Bertina R. M., Vos H. L. |
| |
|
Identification of two novel point mutations in XIII A chain gene associated with congenital deficiency in a Chinese FXIII deficiency family
|
| Cai W., Wang W., Liu G., Cheng S., Bao C. |
| |
|
Idiopathic thrombocytopenic purpura at children, associated with a virus of rubella
|
| Petrov V. Y., Plahuta V. Y., Yakunina L. N., Soskov G. I., Vdovin V. V., Ageenkova E. V. |
| |
|
IgG antiphosphatidylserine and anti-b2GPI are better predictors of arterial and venous thrombosis than anticardiolipin antibodies in antiphospholipid syndrome
|
| Dier K. J., Lopez D., Fink C. A., Merrill J. T., Lopez L. R. |
| |
|
IgG antiprothrombin antibodies from patients with antiphospholipid syndrome inhibit the inactivation of Factor Va by activated protein C
|
| Galli M., Willems G., Rosing J., Janssen R., Govers J., Barbui T., Zwaal R. F. A., Bevers E. M. |
| |
|
IgG autoantibodies to OxLig-1/B2GPI complex are associated with arterial thrombosis in patients with anti-phospholipid syndrome
|
| Lopez D., Merrill J. T., Matsuura E., Lopez L. R. |
| |
|
IgG isolated from plasmas of patients with the anti-phospholipid syndrome binds to domain I of beta2-glycoprotein I
|
| De Laat H. B., Derksen R. H. W. M., Iverson G. M., De Groot P. G. |
| |
|
IgG-antibodies (IgG-Ab) against beta-2-glycoprotein I (b2-GPI) are associated with an increased risk for thrombotic events (TE) in patients (pts) with the lupus anticoagulant (LA)
|
| Zoghlami-Rintelen C., Sailer T., Lehr S., Kaider A., Koder S., Ovissi L., Quehenberger P., Lechner K., Pabinger I. |
| |
|
IgM-anticardiolipin – marker of a previous thrombosis?
|
| Miesbach W., Asmelash G., Scharrer I. |
| |
|
IL-6 concentration in the acute phase of deep-vein thrombosis is a strong predictor of elevated venous outflow resistance as a proxy of post-trombotic syndrome
|
| Roumen-Klappe E., Wollersheim H., Holewijn S., Van Der Ven-Jongekrijg J., Pesman G., Den Heijer M. |
| |
|
Imaging and characterization of the procoagulant activity appeared on the surface of platelet thrombi formed on the collagen surface under blood flow conditions
|
| Tamura N., Kitajima I., Tanabe T., Handa S., Goto S. |
| |
|
Immediate anti-coagulant and anti-inflammatory effects of simvastatin and fenofibrate in patients with coronary artery disease
|
| Celinska-Lowenhoff M., Undas A., Domagala T. B., Iwaniec T., Szczeklik A. |
| |
|
Immune tolerance induction in the treatment of children with haemophilia A complicated by factor VIII inhibitor
|
| Klukowska A., Obitko Pludowska A., Laguna P., Zieleniewska B., Malinowska I. |
| |
|
Immunohistochemical expression of interleukin-10 (IL-10) in atherosclerotic intimas of human coronary arteries
|
| Sumiyoshi S., Nakashima Y., Chen Y. X., Itabe H., Sueishi K. |
| |
|
Immuno-phenotypic platelet characteristics distinguish high vs. low risk patients for thrombosis after stent implantation under thienopyridin plus aspirin treatment
|
| Teuma X., Barragan P., Poncelet P., Moulard M. |
| |
|
Impact of direct thrombin inhibitors on actions of vitamin K antagonists on analysis with different coagulation parameters: aPTT and PT for argatroban, hirudin and melagatran
|
| Fenyvesi T., Trager I., Giese C., Jorg I., Harenberg J. |
| |
|
Impact of knowledge of a positive family history on the clinical presentation of hemophilia
|
| Maclean P. E., Fijnvandraat K., Beijlevelt M., Koopman M. M. W., Peters M. |
| |
|
Impact of platelet glycoprotein Ibalpha Kozak polymorphism on risk of ischemic cerebrovascular events
|
| Hsieh K., Unger P., Endler G., Reisinger M., Janisiw M., Lalouschek W., Lang W., Mannhalter C. |
| |
|
Impact of prenatal/perinatal events and early FVIII replacement on inhibitor risk in children with severe hemophilia
|
| Santagostino E., Rocino A., Saladini A., Mannucci P. M. |
| |
|
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
|
| Allen G., Wolberg A.S., Oliver J.A., Hoffman M., Roberts H.R., Monroe D.M. |
| |
|
Impact of reagent choice on the APTT response to argatroban
|
| Francis J., Court N. |
| |
|
Impaired anticoagulant activity of factor V accounts for a large fraction of the APC resistance associated with the FV Leiden (R506Q) and R2 (H1299R) mutations
|
| Castoldi E., Brugge J. M., Nicolaes G. A. F., Tans G., Rosing J. |
| |
|
Impaired flow-mediated vasodilation in vivo and reduced shear-induced platelet reactivity in vitro in response to nitric oxide in prothrombotic, stroke-prone spontaneously hypertensive rats
|
| Taka T., Ohta Y., Seki J., Giddings J. C., Yamamoto J. |
| |
|
Impaired interaction of protein C Gla domain variants with the endothelial cell protein C receptor (EPCR)
|
| Preston R., Villegas-Mendez A., Hermida J., Simioni P., Tormene D., Lane D. A., Simmonds R. E., Philippou H. |
| |
|
Impaired prothrombinase activity of Factor X Gly381Asp results in severe familial CRM + FX deficiency
|
| Pinotti M., Camire R. M., Baroni M., Rajab A., Marchetti G., Bernardi F. |
| |
|
Impaired thrombus formation in a murine model of glycoprotein VI deficiency
|
| Kato K., Kanaji T., Russell S., Kunicki T., Furihata K., Kanaji S., Marchese P., Ruggeri Z., Ware J. |
| |
|
Impaired vascular function in hypertensive pregnancy
|
| Al-Yemeni E., Beevers D. G., Blann A., Lip G. Y. H. |
| |
|
Impairment of fibrynolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients
|
| Iorio A., Ferolla P., Orsini Federici M., Celleno R., Stabile A., Ackwe J., Canonico V., Massi Benedetti M. |
| |
|
Impairment of morphology and NO release in cultured endothelial cells from rabbit coronary vessels following total irradiation by external CO60
|
| Kovalenko T., Parshikov A. V., Osadchenko I. A., Soloviev A. I., Skibo G. G. |
| |
|
Importance of beta-2 glycoprotein I in the lupus anticoagulant cofactor effect: a case report
|
| Eschwege V., Lutters B., Hugel B., Freyssinet J. M., Robert A., De Groot P. G. |
| |
|
Importance of the mobility of the P' region for conformational and functional changes in PAI-1
|
| De Taeye B., Compernolle G., Dewilde M., Biesemans W., Declerck P. J. |
| |
|
Important Role of FV G1691A and FII G20210A in women with pregnancy loss without apparent causes
|
| Krause M., Zwinge B., Vigh TH., Scharrer I. |
| |
|
Improved differentiation between factor V wild type and factor V Leiden patients using a new prothrombin-based activated protein C resistance assay
|
| Calatzis A., Conell B., Dick A., Spannagl A. |
| |
|
Improvements in flow measurements of fibrin network permeation in plasma or purified fibrinogen-thrombin system
|
| He S., Cao H., Blombäck M. |
| |
|
Improving bridge-out therapy with low-molecular-weight heparin in an urban, inner city medical center
|
| Dumo P., Racine E., Popovic B., Gortney J. |
| |
|
Improving efficacy of gene therapy of hemophilia B by the use of mutant FIX variants
|
| Schuettrumpf J., Herzog R. W., Kaufhold A., Stafford D. W., High K. A., Arruda V. R. |
| |
|
Improving the quality of INR determination in the anticoagulation clinic
|
| Milne M., Stevenson K. J., Craig S., Shlebak A., Amponsah E., Mc Carthy P., Allaw A. |
| |
|
Improving VTE prophylaxis standards of care
|
| Dahl O. |
| |
|
In terms of clinical impact, thromboplastins with an ISI close to 1 yield better results than thromboplastins with an ISI close to 2, in an external quality control campaign
|
| Simonnet V., Léger P., Nguyen F., Boneu B., Cambus J. P. |
| |
|
Inactivation of non-enveloped viruses by non-ionic detergent and solvent/detergent in the fibrinogen component of fibrin sealant
|
| Stagg S., Bashford L., Roberts P. L. |
| |
|
Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270
|
| Ding Z., Kim S., Dorsam R. T., Jin J., Kunapuli S. P. |
| |
|
Incidence and risk factors for factor VIII antibodies in mild hemophilia A
|
| Maclean P. E., Menke L. A., Fijnvandraat K., Van Ommen C. H., Meijers J. C. M., Peters M. |
| |
|
Incidence of hyperhomocysteinemia in patients with symptoms of thrombophilia
|
| Gumulec J. |
| |
|
Incidence of major hemorrhages related to surgery in type 1 von Willebrand's disease patients
|
| Woods A., Meschengieser S. S., Blanco A. N., Lazzari M. A. |
| |
|
Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism
|
| Taliani M. R., Agnelli G., Prandoni P., Becattini C., Moia M., Bazzan M., Ageno W., Tomasi C., Guazzaloca G., Bertoldi A., Ambrosio G. B., Salvi R. M., Poggio R., Silingardi M., Imberti D., Porro F., Zonzin P., Casazza F., Pogliani E., Ria L., Piovella F., De Lucia D. |
| |
|
Incidence of recurrent ischemic stroke in children with coagulation abnormalities
|
| Cherubin E., Gentilomo C., Laverda A. M., Zerbinati P., Fadin M., Gavasso S., Drigo P., Battistella P. A., Girolami A., Simioni P. |
| |
|
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors
|
| Baglin T., Luddington R., Brown K., Baglin C. |
| |
|
Incidence of thrombosis in gastro-esophageal cancer: a cohort study of 649 patients
|
| Tesselaar M., Steegh N., Rosendaal F. R., Nortier J. W. R., Osanto S. |
| |
|
Incidence of venous thrombosis in carriers of familial thrombophilia with a personal history of venous thrombosis
|
| Vossen C. Y., Conard J., Fontcuberta J., De Jonge I., Makris M., Van Der Meer F. J. M., Pabinger I., Palareti G., Preston F. E., Scharrer I., Souto J. C., Svensson P., Walker I. D., Rosendaal F. R. |
| |
|
Incidental pulmonary embolism in patients with cancer
|
| Wun T., Johl J., Shelton D. K., Hutchinson K., Wang S., Chew H., White R. |
| |
|
Increase in mitogenic and decrease in contractile P2 receptors in smooth muscle cells by fluid shear stress in intact human conduit vessels
|
| Wang L., Andersson M., Karlsson L., Watson M. A., Cousens D. J., Jern S., Erlinge D. |
| |
|
Increase in platelet VEGF release in early breast cancer
|
| Hewitt J., Temple I., Mcdowell G., Kirwan C., Burton I. E., Bundred N. J., Byrne G. J. |
| |
|
Increased circulating cardiovascular risk factors in obstructive sleep apnoea and the effect of CPAP therapy
|
| Segal H. C., Robinson G. V., Pepperell J. C. T., Giangrande P. L., Davies R. J. O., Stradling J. R. |
| |
|
Increased coagulation factor XIII B subunit antigen and factor XIII biotin activity is associated with family history of stroke in South Asians
|
| Kain K., Young J., Bamford J., Bavington J., Grant P. J., Catto A. J. |
| |
|
Increased expression of endogenous tissue-type plasminogen activator and matrix metalloproteinase 9 contribute to heparin-produced cerebral hemorrhage after focal cerebral ischemia in mice
|
| Ikeda Y., Zhao B.-Q., Umemura K., Ihara H., Suzuki Y., Kondo K., Nagai N., Sato K., Urano T. |
| |
|
Increased factor V level and preanalytical coagulation
|
| Eschwege V., Trillard M., Robert A. |
| |
|
Increased factor XIII B and decreased factor XIII A subunit antigen levels in insulin resistant South Asian patients with ischaemic stroke
|
| Kain K., Young J., Bamford J., Bavington J., Grant P. J., Catto A. J. |
| |
|
Increased fibronectin secretion but not cell surface expression in thrombin-activated platelets of hypofibrinogenemia patients
|
| Zhai Z., Wu J., Xu X., Ding K., Sun Z., Ni H. |
| |
|
Increased intima-media thickness to show relationship between atherosclerosis and inflammation in a human model: patients affected by rheumatoid arthritis and absence of common markers of atherosclerosis
|
| Di Micco P., Cuomo G., Niglio A., Abbadessa S., Valentini G. |
| |
|
Increased levels of endothelial injury marker in close relationship with lipoatrophy in HIV infected patients under high active antiretroviral treatment
|
| De Larrañaga G., Bocassi A. R., Puga L. M., Benetucci B. S., Alonso J. A. |
| |
|
Increased lipoprotein(a) levels as an independent risk factor for idiopathic and recurrent venous thrombosis
|
| Marcucci R., Alessandrello Liotta A., Rogolino A., Lari B., Mannini L., Gori A.M., Lenti M., Abbate R., Gensini G.F., Prisco D. |
| |
|
Increased metastatic potential of tumor cells in von Willebrand factor (VWF)-deficient mice
|
| Terraube V., Lenting P. J., Meyer D., Denis C. V. |
| |
|
Increased neutrophil apoptosis in chronic fatigue syndrome
|
| Kennedy G., Spence V. A., Underwood C., Mclaren M., Belch J. J. F. |
| |
|
Increased plasma isoprostanes and other markers of oxidative stress in chronic fatigue syndrome
|
| Kennedy G., Spence V. A., Mclaren M., Hill A., Belch J. J. F. |
| |
|
Increased plasma tissue factor predicts adverse outcome in chronic heart failure
|
| Blann A., Chin B., Gibbs C., Chung N., Conway D., Lip G. Y. H. |
| |
|
Increased platelet activation in hyperhomocysteinemic patients
|
| Shmeleva V. M., Shitikova A. S., Malefora A., Harrington D. G., Savidge G. F. |
| |
|
Increased platelet adhesion in metastatic cancer
|
| Caine G., Nadar S., Spooner D., Stonelake P., Lip G. Y. H., Blann A. |
| |
|
Increased platelet superoxide anion production in patients with hypertension: role of AT1 receptors
|
| Sanguigni V., Pignatelli P., Germanò G., Lenti L., Ragazzo M., Lauro R., Violi F. |
| |
|
Increased procoagulant activity and impaired fibrinolytic potential in blood mononuclear cells after coronary angioplasty for stable or unstable angina
|
| Semeraro N., Rossiello M. R., Zanna D., Rizzo D., Quagliara D., Rizzon P., Colucci M. |
| |
|
Increased risk for venous thromboembolism and myocardial infarction in family members of patients with prothrombin 20210 A mutation
|
| Bank I., Libourel E. J., Middeldorp S., Hamulyak K., Van Der Meer J., Koopman M. M. W., Van Pampus E. C. M., Prins M. H., Buller H. R. |
| |
|
Increased shear rate threshold in mouse blood for the dependence of platelet thrombus formation on glycoprotein Iba
|
| Ruggeri Z. M., Marchese P., Kanaji T., Mendolicchio L., Ware J. |
| |
|
Increased TAFI-dependent anti-fibrinolytic effect associated with the presence of an anti-FV antibody in a patient with severe thrombophilia
|
| Colucci M., Italia A., Simioni P., Tognin G., Girolami A., Semeraro N. |
| |
|
Increased thrombin potential due to acquired activated protein C resistance in patients with lupus anticoagulants
|
| Regnault V., Béguin S., Wahl D., De Maistre E., Membre A., Hemker H. C., Lecompte T. |
| |
|
Increased thrombin–anti-thrombin III levels in pre-eclampsia and disseminated intravascular coagulation
|
| Whittier A., Simpson D. F., Fink C. A., Lopez L. R. |
| |
|
Increased thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae
|
| Gerlach R., Yahya H., Rohde S., Böhm M., Berkefeld J., Scharrer I., Seifert V., Raabe A. |
| |
|
Increased tissue factor expression in monocytes from patients with anti-phospholipid syndrome depends on NFkB activation
|
| Buendía P., Lopez-Pedrera C., Barbarroja N., Torres A., Aguirre M. A., Dorado G., Cuadrado M. J., Velasco F. |
| |
|
Increased von-Willebrand-facor-binding to platelets in neonatal plasma
|
| Rehak T., Cvirn G., Roschitz B., Muntean W. |
| |
|
Increased VWF antigen clearance in partial quantitative von Willebrand factor deficiency and reporting of a familial tendency
|
| Millar C. M., Riddell A. F., Bell R. J., Warrington C. M., Pascoe G. M., Lee C. A., Brown S. A. |
| |
|
Increasing the dosage of aspirin before percutaneaous coronary intervention: is there any effect in aspirin resistant patients? A randomized study
|
| Hézard N., Metz D., Droullé C., Nazeyrollas P., Potron G., Nguyen P. |
| |
|
Individual variations of the level of oral anticoagulation in patients with venous thromboembolism (VTE) as predictor of clinical outcome
|
| Veeger N. J. G. M., Piersma M., Van Der Meer J. |
| |
|
Individualizing the risk of venous thromboembolism in medical and surgical patients: development of the decision matrix for VTE prophylaxis
|
| Samama M. M., Dahl O. E., Mismetti P., Quinlan D. J., Rosencher N., Cornelis M., Kahan J. P., DECISIONMATRIX TASKFORCE GROUP* |
| |
|
Induction of fractalkine by endothelial cells under shear stress
|
| Moatti D., Vele O., Nemerson Y. |
| |
|
Induction of monocytic tissue factor (TF) expression: an additional mechanism of action of desmopressine acetate (DDAVP)
|
| Poetzsch B., Mueller J., Rox J., Niermann D., Madlener K. |
| |
|
Induction of serum hepatocyte growth factor/activin/follistatin system during enoxaparin-anti-coagulated hemodialysis
|
| Borawski J., Naumnik B., Mysliwiec M. |
| |
|
Inefficient secretion and intracellular degradation of factor V
|
| Yamazaki T., Nicolaes G. A. F., Sorensen K. W., Dahlback B. |
| |
|
Inferior vena cava filters: personal experience on 322 devices, with regard also to medical treatment during long-term follow-up
|
| Quintavalla R., Larini P., Marcato C., Pattacini C., Tagliaferri A., Manotti C. |
| |
|
Inflammation and endothelial dysfunction in patients with carotid stenosis
|
| Notø A., Mathiesen E. B., Vissac A. M., Amiral J., Brodin E., Joakimsen O., Hansen J. B. |
| |
|
Inflammation and thrombogenic activity in terminal heart failure patients and heart transplantation: a prospective study
|
| Vila V., Reganon E., Martinez-Sales V., Martín J., Aznar J., Villa P., Almenar L., Vila V. |
| |
|
Inflammation and thrombosis - Collen Foundation Lecture
|
| Esmon C. T. |
| |
|
Inflammatory factors in patients with acute coronary syndromes. Is there any fluctuation with smoking or cholesterol levels?
|
| Koziri A., Avramakis G., Sfiridaki K., Zaharaki A., Georgas G., Defilippis L., Tsoutsoumanou K., Manousakis E., Kalokiri R., Dermitzakis A. |
| |
|
Inflammatory modulation of alveolar coagulation inhibition in a mouse model of acute respiratory distress syndrome (ARDS)
|
| Bock S. C., Sundar K. M., Zuo Y., Terry C. M., Callahan K. S., Lu A. |
| |
|
Influence of acute cigarette exposition and of a 2-week substitution with folic acid on parameters of blood coagulation, fibrinolysis and homocysteine in healthy smokers
|
| Stricker H. |
| |
|
Influence of anti-thrombin on platelet adhesion onto immobilized fibrinogen in simulated low flow in vitro system
|
| Loncar R., Stoldt V., Zotz R. B., Niesen T., Hellmig S., Scharf R. E. |
| |
|
Influence of argatroban alone and combined with oral anticoagulants on the assessment of coagulation factors
|
| Walenga J. M., Drenth A., Mayuga M., Hoppensteadt D., Harder S., Watanabe H., Osakabe M., Breddin H. K. |
| |
|
Influence of cytochrome P450 2C9 polymorphisms on warfarin maintenance dose in very elderly patients
|
| Siguret V., Pautas E., Gouin I., Catrix M., Andreux J. P., Golmard J. L. |
| |
|
Influence of factor VIII (fVIII) levels in patients treated with DDAVP on the activated protein C resistance (APCR)
|
| Gennari L., Blanco A. N., Grosso S. H., Farías C. E., Lazzari M. A. |
| |
|
Influence of fibrin clot surface structures on processes interaction with fibrinolytical systems components
|
| Savchuk A. |
| |
|
Influence of flow on inhibition of platelet dependent thrombin generation by an anti-GPIIb/IIIa antibody
|
| Thomas S., Rigsby P., Goodall A. H., Gray E. |
| |
|
Influence of heparin-like plant component on fibrinolysis
|
| Lyapin G., Smolina T. Y., Lyapina I. N., Uspenskaya M. S. |
| |
|
Influence of hypophysectomy on hemostasis in chickens
|
| Kuznik B., Pateyuk A. |
| |
|
Influence of intraluminal thrombus on cellular and structural features of the aneurysm wall
|
| Kazi M., Frebelius S., Thyberg J., Eriksson P., Hedin U., Swedenborg J. |
| |
|
Influence of monocyte on lymphocyte-platelet adhesion
|
| Solpov A., Bobrovitch B. |
| |
|
Influence of nadroparin on homocysteine level in aspirin-treated patients
|
| Korzh O. |
| |
|
Influence of oxidatively modified low-density lipoproteins on platelet function
|
| Suttnar J., Otahalova E., Dyr J. E., Cermak J. |
| |
|
Influence of peloidotherapy on hemostasis, cytokines productions and lymphocyte-platelet adhesion
|
| Edelev D., Mikhailenko L., Yurchuk S., Vitkovsky YU. |
| |
|
Influence of platelet glycoprotein IIIa PlA polymorphism on mean platelet volume and vWF after coronary stent implantation
|
| Kottmann T., Piper C., Farr M., Wiemer M., Schmidt M., Kleesiek K., Horstkotte D. |
| |
|
Influence of R353Q factor VII gene polymorphism on the plasma FVII levels in a French native population (The Fitenat Study)
|
| Adotevi O., Tournois C., Thomas S., Mazoyer E., Gueguen R., Bal dit Sollier C., Guillin M. C., Drouet L. |
| |
|
Influence of selective nonpeptide PAR-1 and PAR-4 antagonists on thrombin-induced aggregation of human platelets
|
| Simonet S., Rupin A., Coumailleau S., Henlin J. M., Fauchère J. L., Lavielle G., Verbeuren T. J. |
| |
|
Influence of streptokinase on the hemostasis system parameters
|
| Krasnobrizha E. |
| |
|
Influence of tetramethylpyrazine on the expression of tissue factor induced by proinflammatory cytokines in endothelial cells
|
| Wen Z. B., Xiong S. L., He X. F., He S. L. |
| |
|
Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (VTE) following major orthopedic surgery
|
| Eriksson B., Bauer K. A., Lassen M. R., Turpie A. G. G. |
| |
|
Influence of thrombophilia on efficacy of warfarin for prevention of recurrent venous thromboembolism: results from a randomized trial
|
| Kearon C., Ginsberg J. S., Kovacs M., Anderson D. R., Julian J., Mackinnon B., Weitz J., Crowther M., Wells P., Dolan S., Turpie A. G. G., Geerts W., Solymoss S., Van Nguyen P., Demers C., Kahn S., Kassis J., Rodger M., Hambleton J., Gent M. |
| |
|
Influence of time interval after sampling on variability of thrombelastography (TEG) results
|
| Kretschmer V., Daraktchiev A. |
| |
|
Influence of vitamin supplementation on homocysteine and cysteine concentrations in blood
|
| Keijzer M. B. A. J., Blom H. J., Den Heijer M. |
| |
|
Influence of warfarin use on symptoms of fatigue: a randomized cross-over trial
|
| Kovacs M., Kearon C., Julian J., Mackinnon B., Douketis J., Demers C., Wells P., Turpie A. G. G., Anderson D. R., Kahn S., Van Nguyen P., Green D., Kassis J., Geerts W., Ginsberg J. S. |
| |
|
Inheritable thrombophilias in women with high risk of obstetric complications in the Moscow population
|
| Guzov I. I., Patrushev L. I., Kovalenko T. F., Kukhoreva T. A. |
| |
|
Inherited and de novo von Willebrand disease ‘Vicenza’ in UK families with the R1205H mutation
|
| Lester W. A., Guilliatt A. M., Surdhar G. K., Enayat M. S., Hill F. G. H. |
| |
|
Inherited and acquired prothrombotic risk factors in women with early or late pregnancy losses
|
| Iglesias Varela M. L., Adamczuk Y., Cerrato G., Martinuzzo M., Forastiero R. |
| |
|
Inherited coagulation disorders in southern Iran
|
| Karimi M., Yarmohammadi H., Ardeshiri R., Yarmohammadi H. |
| |
|
Inherited platelet-based bleeding disorders
|
| Cattaneo M. |
| |
|
Inherited prothrombotic risk factors in a Brazilian cohort with CVT
|
| D'Amico E., Camargo E. C. S., Villaça P. R., Massaro A. R., Bassitt R. P., Bendit I., Silva C. S. S., Bacheschi L. A., Scaff M., Chamone D. A. F. |
| |
|
Inherited risk factors are different in pregnant and nonpregnant women with venous thromboembolism
|
| Maakaroun A., Gadan C., Delahousse B., Fimbel B., Marret H., Gruel Y. |
| |
|
Inherited thrombophilia and associated risk for unexplained fetal loss
|
| De Stefano V., Rossi E., Ferrazzani S., De Carolis S., Za T., D'Orazio A., Caruso A., Leone G. |
| |
|
Inherited thrombophilia and hyperhomocysteinemia in upper limb deep vein thrombosis
|
| Passamonti S., Martinelli I., Battaglioli T., Zighetti M. L., Mannucci P. M. |
| |
|
Inherited thrombophilia is not associated with an increased risk of intrauterine fetal death
|
| Verdy E., Berkane N., Magdelaine A., Soubrier F., Uzan S. |
| |
|
Inherited thrombophilias are not increased in ‘idiopathic’ small for gestational age pregnancies
|
| Mccowan L. M. E., Craigie S., Taylor R. S., Ward C., Mclintock C., North R. A. |
| |
|
Inhibition by prothrombin of individual activated protein C-mediated cleavages in factor Va
|
| Tran S., Norstrøm E., Dahlbäck B. |
| |
|
Inhibition of 3-Hydroxy-3-methylglutaryl coenzyme-A reductase attenuates expression of inducible nitric oxide synthase in cardiac myoblasts – Possible link to direct myocardial protection during ischemia-reperfusion
|
| Madonna R., Di Napoli P., Grilli A., Felaco M., Geng Y. - J., De Caterina R. |
| |
|
Inhibition of angiogenesis by statins: a possible contribution for the protection of the vascular risk in atherosclerotic patients
|
| Vincent L., Li H., Vannier J. P., Soria J., Soria C. |
| |
|
Inhibition of anti-phospholipid antibody-induced monocyte tissue factor activity by dipyridamole and dilazep: role of adenosine
|
| Zhou H., Roubey R. A. S. |
| |
|
Inhibition of blood coagulation by ximelagatran in patients with a first episode of symptomatic acute deep venous thrombosis for prophylaxis of recurrent events
|
| Harenberg J., Fenyvesi T., Jorg I. |
| |
|
Inhibition of coagulation and thrombin-mediated platelet aggregation by plasmin-cleaved fibrinogen g'-chain carboxyl terminal peptide
|
| Lovely R. S., Boshkov L. K., Farrell D. H. |
| |
|
Inhibition of factor VIII binding to phospholipids by single-chain variable domain fragments indicates that F2200 plays a more important role than M2199 in membrane-binding
|
| Lewis D. A., Pound M. L., Voorberg J., Ortel T. L. |
| |
|
Inhibition of FVIII coagulation activity by FVIII-light-chain-specific antibodies of haemophilia A patient
|
| Kallas A., Pooga M., Saint-Remy J. M. |
| |
|
Inhibition of human neutrophils plasminogen activation by elastase-derived apolipoprotein(a) fragments
|
| Lamanuzzi L., Anglés-Cano E., Pepe G. |
| |
|
Inhibition of human prothrombinase by PD0313052 reveals advantages of active site-directed factor Xa inhibition
|
| Gould W. R., Welch K. M., Bryant J. W., Leadley R. J. |
| |
|
Inhibition of metalloproteases during platelet storage leads to better platelet recovery and improved platelet function upon transfusion
|
| Bergmeier W., Burger P., Piffath C., Nieswandt B., Wagner D. D. |
| |
|
Inhibition of P2Y12-receptor in vivo and in vitro in patients undergoing elective percutaneous coronary intervention (PCI)
|
| Lepäntalo A., Virtanen K. S., Lassila R. |
| |
|
Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia
|
| Renckens R., Weijer S., De Vos A. F., Pater J., Meijers J. C., Hack C. E., Levi M., Van Der Poll T. |
| |
|
Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation
|
| Schäfer A., Fraccarollo D., Hildemann S. K., Eigenthaler M., Kobsar A., Ertl G., Walter U., Bauersachs J. |
| |
|
Inhibition of platelet secretion-induced neutrophil activation by ELR peptide derivatives
|
| Culligan K. G., Connelly P., Foley V., Moran V. |
| |
|
Inhibition of procarboxypeptidase U by tinzaparin. A potential mechanism of its profibrinolytic actions
|
| Florian-Kujawski M., Tobu M., Schultz C., Hoppensteadt D., Fareed J. |
| |
|
Inhibition of retinal neovascularization in mice by antisense phosphorodiamidate morpholino oligomer against av integrins
|
| De Sousa M. A., Davies M. H., London C. A., Powers M. R., Devi G. R., Farrell D. H. |
| |
|
Inhibition of tissue factor initiated thrombosis in vivo
|
| Marzec U. M., Hanson S. R. |
| |
|
Inhibitor against factor VIII in developing countries; the first case of immune tolerance induction in Iran
|
| Baghaipoor M., Rastegar Lari G. |
| |
|
Inhibitors and their management using immune tolerance induction therapy
|
| Hay C. |
| |
|
Inhibitors of NFkB and p38 kinase abrogate tissue factor up-regulation by anti-phospholipid antibodies
|
| Pierangeli S. S., Ferrara D. E., Harris E. N., Swerlick R. |
| |
|
Inhibitory effects of andrographolide on lipopolysaccharide-induced tissue factor expression in human monocytic THP-1 cells
|
| Li Y. M., Hsiao G., Yen M. H. |
| |
|
Inhibitory effects of human anti-factor VIII monoclonal antibodies and their neutralization by respective anti-idiotypic antibodies using Thrombin Generation Test
|
| Raut S., Gilles J. G. G., Saint-Remy J. M. R., Barrowcliffe T. W. |
| |
|
Inhibitory mechanism of rat aortic vascular smooth muscle cell proliferation by NQ12, a novel antithrombotic agent
|
| Yun Y., Jeon J., Ryu C., Kim J., Kim S., Pyo H. |
| |
|
Inhibitory mechanisms of magnesium sulfate on platelet aggregation in in vitro and in vivo experiments
|
| Sheu J., Shen M. Y., Hsiao G. |
| |
|
Injection of the inflammatory peptide fMLP in the rabbit induces transient myocardial ischemia: role of thromboxane A2
|
| Evangelista V., DELL'Elba G., Manarini S., Pecce R., Celardo A., De Gaetano G., Cerletti C. |
| |
|
Innovation in the treatment of venous thromboembolism
|
| Eriksson H. |
| |
|
Insufficient F IX-recovery after treatment with recombinant F IX compared to plasma-derived F IX
|
| Zieger B., Blessing K., Ehl S., Sutor A. H. |
| |
|
Insufficient thromboxane A2 inhibition in patients with vascular disease chronically treated with aspirin: implications for platelet function
|
| Vallés J., Santos M. T., Aznar J., Martínez-Sales* , Lago A., Cosin J., Tembl J., Dasi M. A., Moscardó A., Piñón M. |
| |
|
Insulin enhances human monocyte tissue factor expression induced by activated platelets via phosphatidylinositol-3-kinase signaling pathway
|
| Murasaki K., Tanoue K., Kawana M., Kasanuki H. |
| |
|
Insulin enhances vascular cell adhesion molecule (VCAM-1) expression in human cultured endothelial cells – a link to the pathogenesis of accelerated atherosclerosis in diabetes
|
| Madonna R., Pandolfi A., Massaro M., Consoli A., De Caterina R. |
| |
|
Insulin resistance status and truncal fat are important determinants of plasminogen activator inhibitor type-1 (PAI-1) levels in HIV infected patients
|
| De Larrañaga G., Bocassi A. R., Galich A., Puga L. M., Alonso B. S., Benetucci J. A. |
| |
|
Integrin a2b1 stimulates platelet spreading through protein tyrosine phosphorylation and calcium mobilization
|
| Inoue O., Suzuki-Inoue K., Frampton J., Dean W. L., Watson S. P. |
| |
|
Integrin aIIbb3 outside-in calcium signals sustain platelet–fibrinogen interactions under flow
|
| Hughan S. C., Goncalves I., Schoenwaelder S. M., Yap C. L., Yuan Y., Jackson S. P. |
| |
|
Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region
|
| Ahrens I., Moran N., Meede G., Connolly P., Fitzgerald D.J., Bode C., Peder K. |
| |
|
Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region
|
| Ahrens I. G., Moran N., Meade G., Connolly P., Fitzgerald D. J., Bode C., Peter K. |
| |
|
Integrin activation upon human platelet adhesion to collagen under flow
|
| Lecut C., Schoolmeester A., Deckmyn H., Jandrot-Perrus M., Heemskerk J. W. M. |
| |
|
Integrin clustering mechanisms explored with a soluble aIIbb3 ectodomain construct
|
| Hantgan R. R., Gibbs W., Alspaugh E., Stahle M. C., Mallett T. C., Rocco M., Aster R. H., Peterson J. A. |
| |
|
Integrins and angiogenesis
|
| Hynes R. |
| |
|
Interacting sites within Talin and the integrin b3 cytoplasmic tail
|
| Kreis S., Melchior C., Tremuth L., Schaffner-Reckinger E., Kieffer N. |
| |
|
Interaction between oxidative stress and chemokines in hemodialyzed patients
|
| Pawlak K., Pawlak D., Mysliwiec M. |
| |
|
Interaction between prothrombotic polymorphisms and lupus anticoagulant in chronic cerebrovascular disease
|
| Kapustin S. I., Elchaninov A. P. |
| |
|
Interaction between thrombophilic genetic mutations and clinical bleeding in patients undergoing chronic oral anti-coagulant treatment
|
| Castori I., Taliani R., Agnelli G., Nenci G. G., Gresele P. |
| |
|
Interaction of CD47 with SHPS-1 negatively regulates platelet function
|
| Kato H., Tomiyama Y., Honda S., Yoshida H., Kashiwagi H., Kosugi S., Shiraga M., Kiyoi T., Honma N., Kurata Y., Matsuzawa Y. |
| |
|
Interaction of factor VIII and von Willebrand factor investigated in a large cohort of von Willebrand disease patients: evaluation of the type 2N variant prevalence
|
| Casonato A., Pontara E., Sartorello F., Bertomoro A., Girolami A. |
| |
|
Interaction of the glycoprotein (GP) Ib-IX/V complex with the platelet collagen receptor GPVI
|
| Lin X., Asazuma N., Satoh K., Lu S., Yatomi Y., Berndt M. C., Ozaki Y. |
| |
|
Interaction of thrombolytic agents with argatroban: pharmacological implications
|
| Hoppensteadt D., Iqbal O., Tobu M., Osakabe M., Watanabe H., Walenga J., Jeske W., Fareed J. |
| |
|
Interactions between tissue factor pathway inhibitor (TFPI) and lipoprotein lipase (LPL) in metabolism of very low density lipoproteins (VLDL)
|
| Brodin E., Svensson B., Notø A. T. W., Hansen J. B. |
| |
|
Interactive session: special patient cases
|
| Monreal M. |
| |
|
INTERCEPT platelets, treated to inactivate pathogens, maintain hemostasis in thrombocytopenic patients: results of the SPRINT trial
|
| Benjamin R. J., Murphy S., Slichter S., Lin J.-S., Corash L., Conlan M. |
| |
|
Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants
|
| Lambert M., Caron C., Duhamel A., Ferrard-Sasson G., Huyghe T., Dubucquoi S., Hachulla E., Hatron P.Y., Devulder B., Goudemand J. |
| |
|
Interest of VASP measurement on patients treated by thienopyridines
|
| Camoin-Jau L., Barragan P., Laibbe S., Teuma X., Dignat-George F., Eigenthaler M., Sampol J. |
| |
|
Interferon and ribavirin in patients with chronic hepatitis C and congenital bleeding disorders
|
| Falantes J., Martínez M., Cisneros J. M., Pérez R. |
| |
|
Intergration of vascular biology and magentic resonance imaging in the understanding of acute coronary systems
|
| Fuster V. |
| |
|
Inter-individual variability in inhibition of platelet activation and aggregation by clopidogrel
|
| Theroux P., Angioi M., Gallo R., Ghitescu M., Frojmovic M. |
| |
|
Interleukin 1b modulates platelet function
|
| Yadigarova Z., Kubatiev A. A. |
| |
|
Interleukin-7-mediated inflammation in unstable angina – possible role of chemokines and platelets
|
| Damås J. K., Wæhre T., Yndestad A., Otterdal K., Hognestad A., Solum N. O., Gullestad L., Frøland S. S., Aukrust P. |
| |
|
Intermolecular forces of individual aIIbb3-fibrinogen and aVb3–osteopontin interactions on platelets
|
| Litvinov R. I., Bennett J. S., Shuman H., Weisel J. W. |
| |
|
International collaborative study on analyzing methods for determination of direct thrombin inhibitors
|
| Gray E., Harenberg J. |
| |
|
Interplay of glycoprotein Iba, integrin a2b1 and glycoprotein VI is required for human thrombus formation under flow
|
| Siljander P. R.-M., Munnix I. C. A., Smethurst P. A., Deckmyn H., Lindhout T., Ouwehand W. H., Farndale R. W., Heemskerk J. W. M. |
| |
|
Interrelation between light and ultrastructure study of bone marrow in thrombocytopenic patients with chronic liver diseases: morphological changes and factors affecting thrombopoiesis
|
| Helmy A., Abdel Aziz I., Adel D., Abdel Rahman Y. |
| |
|
Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII
|
| Clarke B. |
| |
|
Intimatan ameliorates the activation of human platelets by heparin/heparin antibody from patients with heparin-induced thrombocytopenia
|
| Walenga J. M., Prechel M. M., Jeske W. P., Cardin A. D., Van Gorp C., Bakhos M. |
| |
|
Intracellular adhesion molecule-1 is associated with cardiovascular disease in elderly men and women
|
| Swords Jenny N., Arnold A. M., Psaty B. M., Sharrett A. R., Kuller L. H., Fried L. P., Tracy R. P. |
| |
|
Intracellular behavior of anti-thrombin Morioka (Cys95Arg), a mutant protein causing type I deficiency: escape from intracellular protein degradation systems and accumulation within newly formed Russell's body-like structures
|
| Ozawa T., Tanaka Y., Imanaka T., Kitajima I. |
| |
|
Intracellular events in antiphospholipid-mediated platelet activation
|
| Vega-Ostertag M., Harris E. N., Pierangeli S. S. |
| |
|
Intracellular signaling in human endothelial cells induced by the hyaluronan-binding protease
|
| Kreß J., Seitz R., Dodt J., Etscheid M. |
| |
|
Intracellular trafficking of native, full-length, and B-domain-deleted coagulation factor VIII (FVIII) in mammalian cells
|
| Tonn T., Becker S., Simpson J. C., Pepperkok R., Heinz S., Grez M., Seifried E. |
| |
|
Intrasvascular tissue factor procoagulant activity increases following joint replacement surgery
|
| Bach R. R., Johnson G. J., Long J. R., Key N. S. |
| |
|
Intrauterine growth retardation and recurrent pregnancy loss associated with prothrombin gene variants 20221C > T and 20209C > T
|
| Schrijver I., Lenzi T. J., Jones C. J., Lay M. J., Druzin M. L., Zehnder J. L. |
| |
|
Intravenous immunoglobulins G modulate calcium signals, von Willebrand factor secretion and nitric oxide metabolism in human endothelial cells
|
| Rendu F., David-Dufilho M., Schussler O., Pernollet M. G., Brunet A., Le Quan Sang K. H. |
| |
|
Introduction - A Hematologist's Perspective on Sepsis related DIC
|
| Hock Toh C. |
| |
|
Intron 1 factor VIII gene inversion in patients with severe hemophilia A
|
| Salviato R., Belvini D., Radossi P., De Biasi E., Risato R., Davoli P. G., Tagariello G. |
| |
|
Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms
|
| Franchi F., Cetin I., Todros T., Antonazzo P., Nobile De Santis M. S., Cardaropoli S., Piccoli E., Bucciarelli P., Faioni E. M., Biguzzi E. |
| |
|
Investigation of plasma related influence factors of a new protein S activity assay (protein S Ac®)
|
| Patzke J., Merz M., Siegmund A. |
| |
|
Investigation of residues in the fibrin(ogen) gamma chain involved in t-PA binding and plasminogen activation
|
| Wilhelm S. E., Lounes K. C., Lord S. T. |
| |
|
Investigations on the regulation of vascular smooth muscle cell migration by tissue factor (CD142)
|
| Ettelaie C., James N. J., Pradier A., Ooi Y. C., Mccollum P. T. |
| |
|
Involvement of the aIIb subunit in postligand binding signaling events
|
| Schaffner-Reckinger E., Salsmann A., Kabile F., Kieffer N. |
| |
|
Involvement of the p110d catalytic subunit of phosphatidylinositol 3-kinase in platelet spreading on fibrinogen
|
| Senis Y., Atkinson B. T., Wonerow P., Vigorito E., Pearce A. C., Turner M. |
| |
|
Involvement of VEGF-C/flt-4 system in therapeutic angiogenesis of FGF-2 gene transfer in murine ischemic hind limb
|
| Onimaru M., Yonemitsu Y., Tanii M., Tsutsumi T., Nakagawa K., Nakashima Y., Sueishi K. |
| |
|
Irradiated endothelial cells promote platelet aggregates at high wall shear rate
|
| Gaugler M. H., Vereycken-Holler V., Aigueperse J. |
| |
|
IRS-1 mediates platelet inhibition by insulin via the inhibitory G-protein Gi
|
| Andrade Ferreira I., Eybrechts K. L., Kroner C., Akkerman J. W. N. |
| |
|
Is an antithrombin substance (aFIIa) more hemorrhagic compared with an anti-factor Xa (aFXa) aent?: Differential inhibitory effects of these two agents against platelet activation
|
| Yamazaki M, Kaneda M., Yoshida T., Kawashima Y., Ontachi Y., Mizutani T., Ito T., Asakura H., Morishita E., Nakao S. |
| |
|
Is aspirin resistance more common in Black patients?
|
| Cohen H. W., Billett H. H., Monrad E. S. |
| |
|
Is HIT still a medical problem?
|
| Breddin H.K. |
| |
|
Is homocysteine an independent risk factor for myocardial infarction? Results from the Glasgow myocardial infarction study
|
| Woodward M., Rumley A. G., Rumley A., Lowe G. |
| |
|
Is infection a risk factor of acute ischemic stroke?
|
| Nosál M., Blazeková A., Sakalová A., Kotulová D., Ondrejka P., Sedlák P. |
| |
|
Is inflammation involved in the development of thrombosis in patients with the lupus anticoagulant?
|
| Sailer T., Vukovich T., Lehr S., Koder S., Quehenberger P., Panzer S., Lechner K., Pabinger I., Zoghlami-Rintelen C. |
| |
|
Is isolated postmethionine-load hyperhomocysteinemia a separate risk factor for venous thrombosis?
|
| Blom M. B. A. J., Keijzer H. J., Bos G. M. J., Rosendaal F. R., Den Heijer M. |
| |
|
Is plasma homocysteine concentration different in diabetic and nondiabetic stroke patient up to the age of 55?
|
| Sobol A., Bald E., Chwatko G., Stanczyk L., Drzewoski J. |
| |
|
Is sulodexide an alternative treatment in the prophylaxis of thromboembolic disease?
|
| Lasierra J., Coronel P., Cuevas B., Benedicto D. |
| |
|
Is the G455A polymorphism of the fibrinogen beta gene associated with osteonecrosis? A preliminary report
|
| Zalavras C., Giotopoulou S., Zibis A. H., Dokou E., Dailiana Z., Tzolou A., Malizos K. N., Kolaitis N., Vartholomatos G. |
| |
|
Is there an hypercoagulable state after treadmill exercise in patients with atrial fibrillation?
|
| Koziri A., Zaharaki A., Avramakis G., Sfiridaki K., Defilippis L., Manousakis E., Tsoutsoumanou K., Lambrogiannakis E., Georgas G., Ploumidis L. |
| |
|
Ischemia induces early and enhanced expression of a new transcription factor (6A3-5) in human and rat kidney vascular smooth muscle cells
|
| Garin G., Badid C., Vincent M., Mcgregor B., Guerret S., Meugnier E., Hurlstone A., Mcgregor J. L. |
| |
|
Ischemia/reperfusion induces binding of circulated immunoglobulins to the blood vessels in vivo
|
| Bobrovnik S., Coutinho A., Komisarenko S. V. |
| |
|
Isoform composition of antithrombin (a-AT vs. b-AT) in a covalent antithrombin-heparin complex
|
| Parmar N., Berry L. R., Chan A. K. C. |
| |
|
Isolated sustained elevated antib2 Glycoprotein 1 antibodies: association with primary anti-phospholipid syndrome and thrombotic events
|
| Hampton K., Brookfield C., Williams L., Kitchen S. |
| |
|
Isolated thrombocytopenia as a preliminary feature of antiphospholipid syndrome in patients with chronic liver disease
|
| Elbaz O., El-Gamal S., Bahgat M., Moheb M. |
| |
|
Isolation and administration effect of fibrinolysis accelerating substance (FAS) in the fermented soybean food, natto
|
| Sumi H., Yatagai C., Ohsugi T. |
| |
|
Issues arising in application of the ISTH disseminated intravascular coagulation (DIC) scoring system: the need for modification before prospective validation
|
| Rapson D., Dwyre L., Heyland D. K., Giles A. R. |
| |
|
Issues in monitoring direct thrombin inhibitors: comparison of a new, rapid Ecarin Clotting Time (ECT) test to activated clotting time (ACT) and anti-IIa assays
|
| Kaldus T., Cho L., Davis R., Swan H., Lincoff A. M., Moliterno D. J., Kottke-Marchant K. |
| |
